Our findings that low-dose IFN-α modulates breast cancer invasion and adhesion is notable in that it posits a potential anti-tumor clinical benefit through multiple mechanisms of action, without the morbidity of high-dose treatment. This evidence concerns the gene IFNA1 and breast cancer.